InvestorNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives Fast Track Designation for Lead Investigational Drug

Stock Information for WPD Pharmaceuticals Inc - Ordinary Shares

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About WPD Pharmaceuticals Inc - Ordinary Shares

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287
CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.